JNJ ▲ +0.3% - Johnson & Johnson $JNJ - New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma Johnson & Johnson rose 0.3% following positive data from a model-based analysis showing that its combination of TECVAYLI and DARZALEX FASPRO demonstrated potential to extend long-term survival in early-line relapsed/refractory multiple myeloma patients. The favorable analysis supports the therapeutic promise of this drug combination in a significant patient population, which could bolster the commercial outlook for both oncology assets. 23-SEP-2026 09:48 AM ET